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Effects of a 3-Hydroxy-3-Methylglutaryl Coenzyme A
Reductase Inhibitor, Fluvastatin, on Coronary Spasm
After Withdrawal of Calcium-Channel Blockers
Hirofumi Yasue, MD,* Yuji Mizuno, MD,* Eisaku Harada, MD,* Teruhiko Itoh, MD,*
Hitoshi Nakagawa, MD,* Masafumi Nakayama, MD,† Hisao Ogawa, MD,† Shinji Tayama, MD,‡
Takasi Honda, MD,‡ Seiji Hokimoto, MD,§ Shuichi Ohshima, MD,§ Youichi Hokamura, MD,
Kiyotaka Kugiyama, MD,¶ Minoru Horie, MD,# Michihiro Yoshimura, MD,** Masaki Harada, MD,††
Shiroh Uemura, MD,‡‡ Yoshihiko Saito, MD,‡‡ for the SCAST (Statin and Coronary Artery Spasm
Trial) Investigators
Kumamoto, Yamanashi, Shiga, Tokyo, Kyoto, and Nara, Japan
Objectives The purpose of this study was to determine whether a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
(statin) suppresses coronary spasm.
Background Coronary spasm is associated with endothelial dysfunction. Statins have been shown to improve endothelial
function.
Methods This was a prospective, randomized, open-label, end point study. Sixty-four patients who had no significant or-
ganic coronary stenosis and in whom coronary spasm was induced by intracoronary injection of acetylcholine
(ACh) were randomly assigned to fluvastatin 30 mg/day plus the conventional calcium-channel blocker (CCB)
therapy (31 patients, statin group) or the conventional CCB therapy (33 patients, nonstatin group). After 6
months of treatment, the intracoronary injection of ACh was repeated and the coronary spasm was assessed.
Results Coronary spasm was suppressed in 16 of the 31 patients (51.5%, p  0.0001) of the statin group and in 7 of
the 33 patients (21.2%, p  0.0110) of the nonstatin group after 6 months of treatment. Thus, the number of
patients with ACh-induced coronary spasm was significantly reduced in the statin group as compared with the
nonstatin group (51.6% vs. 21.2%, p  0.0231) after 6 months of treatment.
Conclusions The addition of fluvastatin 30 mg/day to the conventional CCB therapy for 6 months significantly reduced the
number of patients with ACh-induced coronary spasm as compared with the conventional CCB therapy. Thus, a
statin (fluvastatin) may possibly be a novel therapeutic drug for coronary spasm. (J Am Coll Cardiol 2008;51:
1742–8) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.049(
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Pt is established that coronary spasm plays an important role
ot only in the pathogenesis of variant angina but also in
schemic heart disease in general, including resting angina,
ffort angina, acute myocardial infarction, and sudden death
1,2). Calcium-channel blockers (CCBs) have been shown
o be highly effective in suppressing coronary spasm and are
idely used as the standard therapy for coronary spasm
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nd lethal arrhythmias and/or sudden death occur in some
f them (1). We have shown that endothelial nitric oxide
NO) activity is reduced and endothelial function impaired
n the coronary arteries involved in spasm (1,5). There is
ncreasing evidence that 3-hydroxy-3-methylglutaryl coen-
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May 6, 2008:1742–8 Suppression of Coronary Spasm With a Statinyme A reductase inhibitors (statins) improve endothelial
ysfunction and reduce cardiovascular events in patients with
oronary artery disease (6–9). Thus, it is possible that statins
ay also suppress coronary spasm and prove to be a novel
herapy for coronary spasm. However, no studies have been
one to test this hypothesis.
The present study was designed to examine whether
ddition of a statin to the conventional CCB therapy would
esult in greater reduction in coronary spasm as compared
ith the conventional CCB therapy.
ethods
atients. The SCAST (Statin and Coronary Artery Spasm
rial) trial was a prospective randomized open-label end
oint study to examine the effect of a statin (fluvastatin)
dded to the conventional therapy on coronary spasm. We
ecruited 78 participants between January 2002 and Decem-
er 2005 from 9 hospitals in Japan. Entry criteria were
ubjects who were 30 to 80 years of age who underwent
oronary angiography because of chest pain and/or ischemic
CG changes on exercise and had no organic coronary
tenosis (50%) and in whom coronary spasm was induced
y intracoronary injection of acetylcholine (ACh). Coronary
pasm was defined as a total or subtotal obstruction or severe
iffuse constriction of an epicardial coronary artery associ-
ted with transient myocardial ischemia as evidenced by
schemic ST-segment changes on ECG. Exclusion criteria
ncluded recent myocardial infarction, acute coronary syn-
rome, heart failure, liver disease, creatinine level 1.5
g/dl, acute inflammation, malignant diseases, and
holesterol-lowering medication within a month. These 78
atients were registered and randomly assigned to either the
tatin group (fluvastatin 30 mg/day plus conventional ther-
py, n  39) or the nonstatin group (conventional therapy,
 39) by using a random number generating computer
ystem. The conventional therapy consisted of CCBs (slow-
elease diltiazem 100 to 200 mg/day, or slow-release nifed-
pine 20 to 40 mg/day). The protocol of this study was
pproved by all site institutional review boards and each
atient provided written informed consent.
nduction of coronary spasm. Coronary spasm was in-
uced by intracoronary injection of ACh after diagnostic
atheterization in the morning. The details of the method
ere previously reported (10). In brief, nitrates, CCBs,
eta-adrenergic blockers, angiotensin converting enzyme
nhibitors, angiotensin receptor blockers, and other vasodi-
ators or vasoconstrictors were withheld for 48 h. ACh
as injected in incremental doses of 50 and 100 g into the
eft coronary artery and then 50 g into the right coronary
rtery under continuous monitoring of ECG and blood
ressure. Coronary spasm induced by this method usually
isappeared spontaneously within 1 to 2 min, and both the
eft and right coronary arteries could be examined separately
nless severe spasm occurred in the left coronary artery and
ecessitated the prompt injection of isosorbide dinitrate into the artery. After the end of the
est, isosorbide dinitrate (0.1 mg)
as injected into the coronary
rtery and angiography was again
erformed.
reatment and follow-up.
ach patient was evaluated at 1, 3,
nd 6 months for assessment of
ngina episodes, drug compliance,
CG, lipid profile, and safety
arkers. At the 6-month follow-
p, patients again underwent cath-
terization after withdrawal of
CBs for a week in both groups,
ut the statin was not withdrawn
n the statin group. Care was taken
o replicate angiographic views, tube height, catheter positions,
nd order of infusions used in the baseline study.
ssessment of coronary artery diameter and ECG
hanges in response to ACh injection. Severe coronary
pasm to a residual lumen diameter 0.4 mm could not be
ccurately quantified because of technical limitations of the
omputer-assisted quantitative coronary angiography (11).
owever, the spasm sites at baseline were identified and the
ame segments and the nonspasm segments proximal to the
pasm sites were evaluated quantitatively at the submaximal
ose of ACh (50 g) in the left coronary artery at baseline
nd follow-up at the core laboratory. Each segment was
eferenced to a specific anatomic landmark for identification
nd films from the baseline and follow-up were examined at
he same time to ensure analysis of the identical portion of
he vessel. The measurement was blinded to the ECG
ndings and the group assignment. An end-diastolic frame
as digitized and the diameter of the index vessel was
easured with CAAS II software (PIE Medical Imaging,
aastricht, Limburg, the Netherlands). Two or 3 sites of
ach segment were measured and the coronary response to
Ch was expressed as the percentage change from baseline
n mean lumen diameter and was compared at the same site
f the same artery in the same patients before and after 6
onths of treatment in each group. The ECG was exam-
ned in a blinded fashion as to the coronary angiographic
ndings and the group assignment at the core laboratory.
aboratory methods. Fasting blood samples were drawn
y venipuncture 1 to 2 days before coronary angiography
nd the hematological and biochemical analyses were done
sing standard laboratory procedures. Serum high sensitivity
-reactive protein was measured in duplicate by automated
mmunoturbidimetric assay using the Synchron LX20 Pro
ystem (Beckman Coulter, Inc., Fullerton, California) (12).
tatistical analysis. The primary end point of the study
as the ACh-induced coronary spasm 6 months after the
reatment. We hypothesized that the induction rate of
oronary spasm in the statin group would be different from
Abbreviations
and Acronyms
ACh  acetylcholine
CCB  calcium-channel
blocker
ECG  electrocardiogram
LCA  left coronary artery
LDL  low-density
lipoprotein
NO  nitric oxide
RCA  right coronary
artery
ROCK  RhoA-associated
kinasehat in the nonstatin group. The number of sample size
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Suppression of Coronary Spasm With a Statin May 6, 2008:1742–8number of patients) (n 76 to 78) was calculated based on
z test at the 2-tailed test 5% significance level and 80%
ower. A 30% treatment effect was considered to be
linically significant, assuming a recurrence rate of coronary
pasm to be 80% to 90% in the nonstatin group. The
econdary end point was the coronary artery diameter
hange in response to the submaximal dose (50 g) of ACh.
or continuous variables, differences between groups were
valuated by unpaired t test or Mann-Whitney rank-sum
est, and those within groups by paired t test or Wilcoxon
igned rank test. For discrete variables, differences were
xpressed as counts and percentages and were analyzed with
hi-square (or Fisher exact) test between groups and with
cNemar test or Fisher exact test within groups, as
ppropriate. A 2-tailed p value of 0.05 was considered to
e statistically significant. Data were expressed as mean 
D. However, when the variable was significantly skewed,
he median (25th, 75th percentile) was reported.
This study was investigator initiated and the drug makers
ad no direct or indirect involvement in the design of the
tudy, provision of the drug, data collection, or preparation
f the manuscript.
Clinical Characteristics of the Study Subjects
Table 1 Clinical Characteristics of the Stud
Variables Statin Group (n  3
Age (yrs) 63.4 12.5
Gender (male/female) 21/10
Body mass index (kg/m2) 23.6 3.4
Hypertension 10/31
Diabetes mellitus 6/31
Current smoker 15/31
Leukocyte (/l) 6,425 1,582
Hemoglobin (g/dl) 13.4 1.7
Platelet (104/l) 22.8 6.0
CRP (mg/l)* 1.94 (0.79, 5.04)
Total protein (g/dl) 6.8 0.5
Albumin (g/dl) 3.98 0.41
Fast blood sugar (mg/dl) 104.3 22.7
AST (U/l) 25.3 11.1
ALT (U/l) 25.6 14.7
CPK (U/l) 113.0 75.4
Total cholesterol (mg/dl) 193.8 36.3
LDL cholesterol (mg/dl) 114.9 33.2
HDL cholesterol (mg/dl) 55.5 13.8
Triglyceride (mg/dl) 130.2 67.0
Medications
Ca-channel blockers 31/31
Diltiazem/nifedipine 20/11
Aspirin 11/31
ACE inhibitor 3/31
ARB 6/31
Nitrate 4/31
Beta-blocker 1/31
Fibrate 1/31
*Median (25th, 75th percentile).
ACE  angiotensin-converting enzyme; ALT  alanine aminotransferase; A
ferase; CPK  creatine phosphate kinase; CRP  C-reactive protein; HDL  hesults
linical characteristics and adverse events. Of the 78
atients randomized, 14 patients were withdrawn (statin
roup: n  8; nonstatin group: n  6). In the statin group,
patient suffered from sudden death during an earthquake,
patient from drug allergy, and 1 patient underwent a
ervical operation. In the nonstatin group, 1 patient could
ot undergo coronary angiography at 6-month follow-up
ecause of trouble at catheterization. The remaining pa-
ients were withdrawn due to unwillingness to undergo the
econd catheterization (statin group: n  5; nonstatin
roup: n  5). Thus, a total of 64 patients (31 patients in
he statin group and 33 patients in the nonstatin group)
ere available for analysis, and all of these patients had
dhered to the protocol. The baseline characteristics of the
treatment groups are shown in Table 1.
Twenty-eight patients of the statin group and 27 patients
f the nonstatin group had episodes of chest discomfort
efore the entry. Twenty-one of the patients (75.0%,
 0.0001) in the statin group and 19 of the patients
70.4%, p  0.001) in the nonstatin group became asymp-
omatic during 6 months of treatment. Thus, CCBs were
jects
Nonstatin Group (n  33) p Value
61.8 10.2 0.6091
18/15 0.2795
24.5 3.7 0.3022
14/33 0.4012
6/33 0.9044
12/33 0.3304
6,228 2,049 0.6689
13.6 1.7 0.6382
22.2 8.3 0.7546
1.36 (0.38, 2.45) 0.3502
6.8 0.4 0.8798
3.97 0.33 0.8989
111.2 39.8 0.4082
24.9 9.3 0.8818
25.7 17.1 0.7874
101.5 63.2 0.5154
193.9 44.2 0.9950
119.7 27.0 0.5366
53.3 15.1 0.5656
134.3 64.7 0.8021
33/33 0.9642
26/7 0.3778
13/33 0.7468
2/33 0.6673
10/33 0.3121
7/33 0.5119
3/33 0.6136
0/33 0.4844y Sub
1)RB  angiotensin II receptor blocker; AST  aspartate aminotrans-
igh-density lipoprotein; LDL  low-density lipoprotein.
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May 6, 2008:1742–8 Suppression of Coronary Spasm With a Statinighly effective in suppressing symptomatic coronary spasm
n both groups in agreement with the results of previous
tudies (1–4), and there was no significant difference (p 
.924) in the incidence of subjective symptoms during the
reatment period between the 2 groups with these sample
izes. Twenty-five patients in the statin group and 22
atients in the nonstatin group underwent 24-h Holter
onitoring on entry, and ischemic ECG changes were
etected in 6 patients (24.0%) of the statin group and in 5
atients (22.7%) of the nonstatin group. After 6 months of
reatment, ischemic ECG changes on Holter monitoring
ere detected in none of the statin group and in 2 patients
f the nonstatin group. No adverse effects were detected in
ither group during the follow-up period.
oronary angiographic and ECG changes in response to
Ch at baseline and after 6 months of treatment. At the
egistration, spasm was induced at 26 left coronary artery
LCA) and at 19 right coronary artery (RCA) in the statin
roup, and at 27 LCA and at 16 RCA in the nonstatin
roup, accompanied by ischemic ECG changes as shown in
able 2. After 6 months of treatment and after withdrawal
f CCBs for 1 week, spasm was induced at 12 LCA and at
0 RCA in the statin group, and at 21 LCA and at 13 RCA
n the nonstatin group, accompanied by ST-segment
hanges as shown in Table 2. The ACh-induced coronary
pasm after 6 months of treatment was similar to that of the
aseline in location and type (total or subtotal obstruction,
r severe diffuse narrowing).
Coronary spasm was suppressed in 16 out of 31 patients
51.6%, p  0.0001) of the statin group and in 7 out of 33
atients (21.2%, p  0.0110) of the nonstatin group after 6
onths of treatment. Thus, the number of patients with
Ch-induced coronary spasm was significantly reduced in
he statin group as compared with the nonstatin group
51.6% vs. 21.2%, p  0.0231) after 6 months of treatment
Fig. 1). The results also revealed that coronary spasm was
nduced in a high proportion of the patients after with-
rawal of CCBs after 6 months of treatment.
Quantitative angiographic analysis showed that vasocon-
trictor response (percent change in luminal diameter) to 50
g ACh of the LCA at the same spasm segment of the
ame patient was significantly reduced in both groups after
month as compared with at baseline (from 35.5 
0.1% to 21.3  16.9%, p  0.0001 in the statin group,
schemic ECG Changes Accompanying ACh-Induced Coronary Spas
Table 2 Ischemic ECG Changes Accompanying ACh-Induced Co
ECG Changes
Statin Group
Baseline 6 Months
LCA ST-segment elevation 11/26 (42.3%) 3/26 (11.5
ST-segment depression 15/26 (57.7%) 9/26 (34.6
Total 26/26 (100%) 12/26 (46.2
RCA ST-segment elevation 10/19 (52.6%) 5/19 (26.3
ST-segment depression 9/19 (47.4%) 5/19 (26.3
Total 19/19 (100%) 10/19 (52.6Ch  acetylcholine; ECG  electrocardiogram; LCA  left coronary artery; RCA  right coronary artery.nd from 36.8  21.6% to 30.1  26.3%, p  0.0221
n the nonstatin group). There was thus a significant
eduction in the constrictor response to ACh in the statin
roup as compared with the nonstatin group (21.3 
6.9% vs. 30.1  26.3%, p  0.0087) after 6 months of
reatment (Fig. 2 left). However, there was no significant
ifference in the response at the nonspasm segments be-
ween the 2 groups (6.6  12.6% in the statin group vs.
10.3  12.8% in the nonstatin group, p  0.1029) after 6
onths of treatment, although the response was signifi-
antly reduced in the statin group (p  0.0337) after 6
onths of treatment (Fig. 2, right).
ipid profile and other laboratory data. The results of
ipid and other laboratory data are shown in Table 3. The
evels of low-density lipoprotein (LDL) cholesterol and
-reactive protein decreased significantly in the statin group
from 114.9  33.2 mg/dl to 86.4  27.6 mg/dl,
 0.0001, and from 1.94 [0.79, 5.04] mg/l to 0.60 [0.25,
.20] mg/l, p 0.0077, respectively), whereas there were no
ifferences in these levels in the nonstatin group, after 6
onths of treatment.
Baseline and After 6 Months of Treatment
ry Spasm at Baseline and After 6 Months of Treatment
Nonstatin Group
p Value Baseline 6 Months p Value
9/27 (33.3%) 6/27 (22.2%)
18/27 (66.7%) 15/27 (55.6%)
 0.0001 27/27 (100%) 21/27 (77.8%) 0.0229
6/16 (37.5%) 5/16 (31.3%)
10/16 (62.5%) 8/16 (50.0%)
 0.0001 16/16 (100%) 13/16 (81.3%) 0.2258
P=0.0231
100%
(31/31)
48.4%
(15/31)
(%)
100
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0
P<0.0001 P=0.0110
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alcium-channel blockers are established as the standard
herapy for coronary spasm (1,3,4). However, coronary
pasm may not be completely controlled even with high
oses of CCBs in a substantial number of patients (1,3,4).
oreover, it is not known how long the drugs should be
dministered for control of coronary spasm (13,14). Coro-
ary spasm occurs most often from midnight to early
orning and is often silent and is usually not induced by
xercise in the daytime (1,14). Moreover, there are daily,
eekly, and monthly, as well as circadian, variations in the
requency of coronary spasm (1,15,16) and the episodes of
oronary spasm may not be detected even with 24-h
mbulatory ECG monitoring as shown in this as well as
revious studies (1,15). Accordingly, we examined the effect
f a statin (fluvastatin) on the coronary spasm induced by
he intracoronary injection of ACh in the present study.
The study showed that the addition of fluvastatin to the
onventional therapy for 6 months significantly reduced the
ccurrence of coronary spasm as compared with the con-
entional therapy. The quantitative angiographic analysis
lso showed that the constrictor response to a submaximal
ose of ACh at the same site of the same spasm segment
Spasm Segment
C
ha
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 D
ia
m
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)
0
-10
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-30
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-50
Baseline 6 Month 
P<0.0001
P=0.0087
ns
P=0.0221
Figure 2 Coronary Artery Diameter Change to ACh Injection
Response of coronary artery diameter to intracoronary injection of acetylcholine (A
of treatment at the spasm segment (left) and the nonspasm segment (right) in th
ipid Profile and Other Laboratory Data at Baseline and After 6 Mo
Table 3 Lipid Profile and Other Laboratory Data at Baseline and
Variables
Statin Group (n  31)
Baseline 6 Months
Total-cholesterol (mg/dl) 193.8 36.3 167.7 35.3
LDL cholesterol (mg/dl) 114.9 33.2 86.4 27.6
HDL cholesterol (mg/dl) 55.5 13.8 59.6 13.9
Triglyceride (mg/dl) 130.2 67.0 113.5 63.1
CRP (mg/l)* 1.94 (0.79, 5.04) 0.60 (0.25, 2.20)
Platelet (104/l) 22.8 6.0 21.6 5.6Median (25th, 75th percentile).
Abbreviations as in Table 1.as reduced significantly in the statin group as compared
ith the nonstatin group, but there was no significant
ifference in the response at the same site of the nonspasm
egment between the 2 groups after 6 months of follow-up.
hus, the present study reveals that the spasm segment was
pecifically responsive to a statin (fluvastatin) as compared
ith the nonspasm segment. Fluvastatin significantly re-
uced the serum level of LDL cholesterol. However, it is
ot known whether the suppression of coronary spasm was
irectly caused by the lowering of LDL cholesterol. Our
revious study shows that elevation of LDL cholesterol is
ot a risk factor for coronary spasm (17). Recent experi-
ental and clinical evidence indicates that statins improve
ndothelial dysfunction and suppress inflammation inde-
endently of cholesterol lowering or through “pleiotropic”
ffects (8,9,18,19). We have shown that endothelial NO
ioactivity was reduced and levels of markers of inflamma-
ion were increased in patients with coronary spasm
1,5,15,20). In the present study, the serum level of
-reactive protein, a marker of inflammation was reduced
ignificantly in the statin group, whereas the level remained
nchanged in the nonstatin group in agreement with the
esults of previous studies (8,9,21,22).
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of Treatment
r 6 Months of Treatment
Nonstatin Group (n  33)
p Value Baseline 6 Months p Value
0.0001 193.9 44.2 206.9 26.5 0.0767
0.0001 119.7 27.0 117.1 29.5 0.6124
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May 6, 2008:1742–8 Suppression of Coronary Spasm With a StatinIn addition to inhibiting cholesterol synthesis, statins are
hown to block the synthesis of isoprenoid intermediates of
he cholesterol biosynthetic pathway, thereby preventing
ranslocation and activation of RhoA (8,19). Emerging
vidence indicates that inhibition of RhoA and its down-
tream RhoA-associated kinase (ROCK) pathway leads to
he elevation of endothelial NO synthase expression and
O activity in conjunction with reduction of inflammation,
s well as proliferation of vascular smooth muscle (8,18,19).
Coronary spasm may be regarded as an abnormal hyper-
ontraction of coronary vascular smooth muscle and accu-
ulating evidence indicates that hypercontraction of vascu-
ar smooth muscle is mainly caused by the enhanced Ca2
ensitization through the activation of the RhoA/ROCK
athway (23–25).
Accordingly, it is reasonable to postulate that the Rho/
OCK pathway plays a key role in the pathogenesis of
oronary spasm (24,25) and statins, including fluvastatin are
ikely to suppress coronary spasm by inhibiting the Rho/
OCK pathway, thereby improving endothelial function,
nhancing NO activity, and suppressing inflammation and
a2 sensitivity of coronary smooth muscle. Indeed, we and
thers (18,26–28) have shown that statins enhance the
xpression of endothelial NO synthase gene in human
ndothelial cells. The present study thus suggested that a
tatin may be a novel disease-modifying drug for coronary
pasm based on the underlying pathogenesis and improve
he overall prognosis for the patients. On the other hand,
oronary spasm was again induced in the majority of the
atients on withdrawal of CCBs after 6 months of treat-
ent without a statin. The results indicated that calcium-
hannel blockade for 6 months might not substantially
odify the underlying pathogenesis of coronary spasm in
he majority of the patients (15) and revealed that CCBs
hould not be withdrawn for at least 6 months.
One previous study reported that a statin reduced coro-
ary vasoconstrictor response to ACh, reflecting improved
ndothelial function in patients with stable coronary artery
isease after 5.5 months of treatment (29). However, other
tudies reported that 6 months of statins therapy had no
ignificant effect on coronary endothelial vasomotor func-
ion in patients with stable coronary artery disease (30,31).
e studied the spasm segment as well as nonspasm seg-
ent in patients with coronary spasm, because no previous
tudies examined the effect of a statin on coronary spasm. It
s interesting to note that the effect of a statin appears within
to 3 months of treatment in patients with unstable
oronary syndrome, whereas it is apparent only after 1 to 2
ears in those with stable coronary artery disease (8,9,32).
ifferent pathophysiological mechanisms of coronary dis-
ase may thus respond differently to a statin.
tudy limitations. Although the present study reveals that
n addition of fluvastatin to the conventional therapy
uppresses coronary spasm, the duration of the study period
as short (6 months) and the number of the study subjects
as small because of the invasive nature of the study foremonstrating coronary spasm. A larger number of patients
nd longer periods of follow-up would be required to
etermine the long-term efficacy and safety of a statin
fluvastatin) for the treatment of coronary spasm by using a
oninvasive and more sensitive method for detection of
oronary spasm. This study thus provides a rationale for the
se of a statin for the treatment of coronary spasm. It is not
et known whether these combination therapies will prove
o be cost-effective and safe for long-term use in patients
ith coronary spasm. We used fluvastatin because the risk
or rhabdomyolysis and the possible drug interaction with a
CB were reported to be lowest and the possible vascular
ffect was highest among the statins clinically available at
he time of initiating this study (33). It thus remains to be
etermined whether statins other than fluvastatin may have
he similar effects on coronary spasm.
onclusions
he present study showed that an addition of fluvastatin 30
g/day to the conventional CCB therapy for 6 months
ignificantly reduced coronary spasm induced by intracoro-
ary injection of ACh as compared with the conventional
herapy. The quantitative angiographic analysis revealed
hat fluvastatin was specifically effective in suppressing the
asoconstrictor response of the spasm segments as compared
ith the nonspasm segments.
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